Live
- A captivating Kuchipudi ballet celebrating divine love and valour
- Divyanka Tripathi took up magic workshop to learn the art of magic for her new show
- Minister unveils design conclave poster
- Sonu Sood Appointed Brand Ambassador and Honorary Tourism Advisor for Thailand
- Ganja cultivation in heart of vizag
- BRS lodges complaint against CM, Minister
- When Preity Zinta embarrassed her mother by stuffing oranges in her clothes
- Cong MLA likens KCR to Godse
- SITAM signs MoU to establish new Labs
- Clear your stand on caste census, Ponam asks BJP
Pharmexcil rebuts superbug charges
The Pharmaceutical Export Promotion Council of India (Pharmexcil) on Thursday stoutly refuted allegations that effluents produced by Indian pharmaceutical companies turned into breeding grounds for antibiotic resistance bacteria, and termed such charges leveled in a recent report in the UK as a conspiracy to defame Indian companies.
Hyderabad: The Pharmaceutical Export Promotion Council of India (Pharmexcil) on Thursday stoutly refuted allegations that effluents produced by Indian pharmaceutical companies turned into breeding grounds for antibiotic resistance bacteria, and termed such charges leveled in a recent report in the UK as a conspiracy to defame Indian companies.
Recently, London-based The Bureau of Investigative Journalism published a report titled “Revealed: How dirty production of NHS drugs helps create superbugs” in which it claimed that “dirty production methods” being practiced by Indian pharma companies were “fuelling the rise of superbugs (antibiotic resistance bacteria)”.
It cited the results of tests carried out by Changing Markets, a campaigner on environmental and social issues, on the water samples collected near drug companies in India. Water samples originating from a manufacturing plant of Aurobindo Pharma in Hyderabad, were found to be producing the highest level of superbug, the report alleged.
“These allegations are baseless because the Indian pharmaceutical industry is controlled by a strong regulatory mechanism for GMP (good manufacturing practices) and environmental controls. This is being enforced by regular audits so as to ensure adherence to the regulatory compliance,” PV Appaji, Director General, Pharmexcil, told the media here.
He said that Pharmexcil was noticing a disturbing trend. “In the recent past, much of adverse propaganda is taking place against the Indian companies with an intention to malign the image of Indian pharma and ultimately depriving the developing world to have an access to the quality drugs manufactured by Indian companies at affordable cost,” he added.
